The interactions of beta amyloid (Abeta) with microglia and endothelial cells in the brains of patients with Alzheimer?s disease (AD) are mediated by specific receptors for Abeta and may play critical roles in the pathogenesis of AD. Microglia are activated by Abeta to produce proinflammatory cytokines and neurotoxins. Abeta-induced cytokines participate in AD pathogenesis by increasing neurotoxin production and up-regulating the expression and activities of the enzymes that promote Abeta formation such as beta and gamma secretase. Endothelial cell binding to Abeta leads to vascular dysfunction and promotes transport of circulating Abeta and its accumulation into the brain. For these reasons, blocking the interactions of Abeta with its cellular receptors is a potential therapeutic strategy for AD. We identified CD36 as a key receptor that mediates cellular interactions of microglia and endothelial cells with Abeta. To determine the exact role of CD36-Abeta interactions in the pathogenesis of AD, we bred CD36-/- mice with PS1-APP double transgenic mice that develop accelerated AD-like pathology. Analysis of the resulting PS1-APP-CD36-/- mice showed that they have a significant reduction in the level of Abeta in their brain when compared to age matched PS1-APP mice with normal CD36 expression. The decrease in Abeta levels in the brains of PS1- APP-CD36-/- mice was associated with a significant reduction in the number of senile-like plaques, and in the inflammtory response associated with these plaques, suggesting that CD36 expression and/or CD36-Abeta interactions regulate Abeta accumulation and the subsequent development of AD-like pathology in these mice. The overall goal of this grant is to identify the mechanism(s) by which CD36 regulates intracerebral Abeta levels in PS1-APP mice. Accumulation of Abeta in the brain is regulated by three pathways, enzymes that generate Abeta, enzymes that degrade Abeta, and the influx/efflux of Abeta across the endothelium and the blood brain barrier. We will determine the role of CD36 in each of these 3 pathways. We will also determine if restoring the CD36-mediated inflammatory response by repopulating the brain of PS1-APP-CD36-/- with CD36+/+ microglia using bone marrow tranplant from CD36+/+ mice will restore AD-like pathology in these mice. The data obtained from these experiments will help decipher this novel CD36-dependent pathway for regulation of intracerebral Abeta levels. Since CD36 expression in human brains correlates with Abeta levels and since CD36 targeted therapeutics are being explored for diseases other than AD, these experiments will also help us determine if targeting CD36 can be used as a disease modifying therapeutic strategy to stop or delay progression of AD.

Public Health Relevance

Effective and safe therapies for Alzheimer?s disease remain elusive. Understanding how CD36 deficiency protects from Alzheimer?s-like disease in mice, is an important and key first step that will allow us to design CD36 targeted therapies that will stop or delay the progression of this devastating disease and therefore help limit its significant health and economic impact on afflicted individuals, their families and society.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Cellular and Molecular Biology of Glia Study Section (CMBG)
Program Officer
Corriveau, Roderick A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
van der Vos, Kristan E; Abels, Erik R; Zhang, Xuan et al. (2016) Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol 18:58-69
Gold, Maike; El Khoury, Joseph (2015) β-amyloid, microglia, and the inflammasome in Alzheimer's disease. Semin Immunopathol 37:607-11
Prabhudas, Mercy; Bowdish, Dawn; Drickamer, Kurt et al. (2014) Standardizing scavenger receptor nomenclature. J Immunol 192:1997-2006
Hickman, Suzanne E; El Khoury, Joseph (2014) TREM2 and the neuroimmunology of Alzheimer's disease. Biochem Pharmacol 88:495-8
Frenkel, Dan; Wilkinson, Kim; Zhao, Lingzhi et al. (2013) Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer's-like disease progression. Nat Commun 4:2030
Hickman, Suzanne E; Kingery, Nathan D; Ohsumi, Toshiro K et al. (2013) The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 16:1896-905
Hickman, Suzanne E; El Khoury, Joseph (2013) The neuroimmune system in Alzheimer's disease: the glass is half full. J Alzheimers Dis 33 Suppl 1:S295-302
Leung, Elaine; Guo, Ling; Bu, Jing et al. (2011) Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex. Neurobiol Aging 32:387-97
Wilkinson, Kim; Boyd, Justin D; Glicksman, Marcie et al. (2011) A high content drug screen identifies ursolic acid as an inhibitor of amyloid beta protein interactions with its receptor CD36. J Biol Chem 286:34914-22
Stewart, Cameron R; Stuart, Lynda M; Wilkinson, Kim et al. (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11:155-61

Showing the most recent 10 out of 14 publications